These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33475012)

  • 21. Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.
    Li Z; Deng J; Sun J; Ma Y
    Front Immunol; 2020; 11():595207. PubMed ID: 33240283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Current Landscape of Immune Checkpoint Blockade in Metastatic Lung Squamous Cell Carcinoma.
    Yuan H; Liu J; Zhang J
    Molecules; 2021 Mar; 26(5):. PubMed ID: 33807509
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
    Bagchi S; Yuan R; Engleman EG
    Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity.
    Lee WS; Yang H; Chon HJ; Kim C
    Exp Mol Med; 2020 Sep; 52(9):1475-1485. PubMed ID: 32913278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Good cops turn bad: The contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer.
    Zhang H; Houghton AM
    Pharmacol Ther; 2021 Jan; 217():107662. PubMed ID: 32805297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune checkpoint inhibitors: a promising anticancer therapy.
    Singh S; Hassan D; Aldawsari HM; Molugulu N; Shukla R; Kesharwani P
    Drug Discov Today; 2020 Jan; 25(1):223-229. PubMed ID: 31738877
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exosomal PD-L1: Roles in Tumor Progression and Immunotherapy.
    Morrissey SM; Yan J
    Trends Cancer; 2020 Jul; 6(7):550-558. PubMed ID: 32610067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Primary and secondary immune checkpoint inhibitors resistance in colorectal cancer: Key mechanisms and ways to overcome resistance.
    Abushukair H; Ababneh O; Zaitoun S; Saeed A
    Cancer Treat Res Commun; 2022; 33():100643. PubMed ID: 36175334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
    Wang S; Xie K; Liu T
    Front Immunol; 2021; 12():690112. PubMed ID: 34367148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
    Choucair K; Morand S; Stanbery L; Edelman G; Dworkin L; Nemunaitis J
    Cancer Gene Ther; 2020 Dec; 27(12):841-853. PubMed ID: 32341410
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer.
    Zou XL; Li XB; Ke H; Zhang GY; Tang Q; Yuan J; Zhou CJ; Zhang JL; Zhang R; Chen WY
    Front Immunol; 2021; 12():689076. PubMed ID: 34992591
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibition.
    Yuan J; Khilnani A; Brody J; Andtbacka RHI; Hu-Lieskovan S; Luke JJ; Diab A; Marabelle A; Snyder A; Cao ZA; Hodi FS
    Eur J Cancer; 2021 Nov; 157():493-510. PubMed ID: 34561127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
    Pérez-Ruiz E; Melero I; Kopecka J; Sarmento-Ribeiro AB; García-Aranda M; De Las Rivas J
    Drug Resist Updat; 2020 Dec; 53():100718. PubMed ID: 32736034
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer.
    Huang K; Hu M; Chen J; Wei J; Qin J; Lin S; Du H
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion.
    Jiang Y; Zhan H
    Cancer Lett; 2020 Jan; 468():72-81. PubMed ID: 31605776
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma.
    Sheng H; Huang Y; Xiao Y; Zhu Z; Shen M; Zhou P; Guo Z; Wang J; Wang H; Dai W; Zhang W; Sun J; Cao C
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors.
    Perrier A; Didelot A; Laurent-Puig P; Blons H; Garinet S
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32708698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
    Qian X; Hu W; Yan J
    Front Immunol; 2022; 13():963533. PubMed ID: 36016946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Human Leukocyte Antigen Class I Antigen-Processing Machinery Upregulation by Anticancer Therapies in the Era of Checkpoint Inhibitors: A Review.
    Sadagopan A; Michelakos T; Boyiadzis G; Ferrone C; Ferrone S
    JAMA Oncol; 2022 Mar; 8(3):462-473. PubMed ID: 34940799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.